Agonist News and Research

RSS
AlphaFold accelerates discovery of potential antipsychotic drugs by outperforming traditional methods

AlphaFold accelerates discovery of potential antipsychotic drugs by outperforming traditional methods

New compound ZTA-26 could be a game-changer in lipid metabolism regulation

New compound ZTA-26 could be a game-changer in lipid metabolism regulation

New nanoparticle-based immunotherapy delays hormone therapy resistance in prostate cancer

New nanoparticle-based immunotherapy delays hormone therapy resistance in prostate cancer

Study elucidates mechanisms behind G protein selectivity and efficacy in adenosine A2A receptor

Study elucidates mechanisms behind G protein selectivity and efficacy in adenosine A2A receptor

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

Weight loss guaranteed! But what impact on your diet? A review of GLP-1 and GIP/GLP-1 interventions

Weight loss guaranteed! But what impact on your diet? A review of GLP-1 and GIP/GLP-1 interventions

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide may reduce smoking risks for diabetes patients

Study unveils dual roles of TNF-α receptors in tissue regeneration and cell death

Study unveils dual roles of TNF-α receptors in tissue regeneration and cell death

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Semaglutide linked to increased risk of severe eye condition NAION in new study

Semaglutide linked to increased risk of severe eye condition NAION in new study

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Semaglutide and very-low calorie diet combo shows superior results in managing type 2 diabetes

Telehealth reduces stigma and barriers for addiction treatment, study finds

Telehealth reduces stigma and barriers for addiction treatment, study finds

TRPC5 gene identified as a diagnostic marker of obesity and postpartum depression

TRPC5 gene identified as a diagnostic marker of obesity and postpartum depression

Breakthrough prosthetic leg achieves natural gait through neural control

Breakthrough prosthetic leg achieves natural gait through neural control

Study reveals exercise and GLP-1 RA combination preserves bone health during weight loss

Study reveals exercise and GLP-1 RA combination preserves bone health during weight loss

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

New drug tirzepatide significantly improves sleep apnea and weight loss

New drug tirzepatide significantly improves sleep apnea and weight loss

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.